Eton Pharmaceuticals

Yahoo Finance • 4 days ago

Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700

DEER PARK, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today an... Full story

Yahoo Finance • 15 days ago

Eton Pharmaceuticals Names Judith Matthews CFO, Effective June 1

(RTTNews) - Eton Pharmaceuticals Inc. (ETON) on Thursday said it has appointed Judith M. Matthews as Executive Vice President, Accounting and Finance, effective immediately. Matthews will assume the role of Chief Financial Officer on June... Full story

Yahoo Finance • 2 months ago

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing

On February 17, 2026, Opaleye Management Inc. reported selling out its entire stake in Immunome(NASDAQ:IMNM), an estimated $37.30 million trade based on quarterly average pricing. What Happened According to its SEC filing dated February... Full story

Yahoo Finance • 2 months ago

Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing

Opaleye Management Inc. disclosed in a February 17, 2026, SEC filing that it sold 180,000 shares of Liquidia(NASDAQ:LQDA), an estimated $5.12 million trade based on quarterly average pricing. What Happened According to a SEC filing dated... Full story

Yahoo Finance • 2 months ago

Eton Pharma Acquires U.S. Commercialization Rights For Hemangeol In Infantile Hemangioma

(RTTNews) - Eton Pharmaceuticals, Inc. (ETON), a commercial-stage pharmaceutical company, Wednesday announced in-licensing of U.S. commercialisation rights to Hemangeo oral solution from Pierre Fabre Medicament SAS, indicated for the treat... Full story

Yahoo Finance • 2 months ago

Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution

DESMODA is the first and only FDA-approved desmopressin oral solutionCommercial launch expected on March 9thDESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing for patients of all agesThe product is ex... Full story

Yahoo Finance • 2 months ago

Catalyst Watch: Nvidia blockbuster, JPMorgan event, and reactions to the tariff reset

[New York City and London multiple exposure image] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY... Full story

Yahoo Finance • 5 months ago

Highlighting December 2025's Growth Leaders With Insider Ownership

As the United States stock market grapples with concerns over an AI bubble, technology shares have been under pressure, causing declines in major indices like the Nasdaq and Dow Jones Industrial Average. In such a volatile environment, com... Full story

Yahoo Finance • 5 months ago

Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th

DEER PARK, Ill., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today ann... Full story

Yahoo Finance • 6 months ago

Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th

DEER PARK, Ill., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today ann... Full story

Yahoo Finance • 6 months ago

Eton Pharma (ETON) Q3 2025 Earnings Transcript

Image source: The Motley Fool. DATE Thursday, November 6, 2025 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Sean BrynjelsenChief Financial Officer — James GruberExecutive Vice President, Corporate Development — David Kre... Full story

Yahoo Finance • 6 months ago

Eton outlines fivefold INCRELEX market opportunity and targets $50M peak adrenal franchise sales amid record Q3 growth

Earnings Call Insights: Eton Pharmaceuticals (ETON) Q3 2025 MANAGEMENT VIEW * Sean Brynjelsen, President, CEO & Director, announced "another record quarter for the company with triple-digit year-over-year revenue growth" and highlighte... Full story

Yahoo Finance • 6 months ago

3 Growth Companies With Insider Ownership Up To 31%

As major stock indexes in the United States continue to reach new heights, driven by significant developments such as Nvidia's landmark $5 trillion market cap and anticipation around Federal Reserve decisions, investors are keenly watching... Full story

Yahoo Finance • 8 months ago

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today ann... Full story

Yahoo Finance • 9 months ago

Eton targets $80M revenue run-rate in Q3 2025 as product launches accelerate

Earnings Call Insights: Eton Pharmaceuticals (ETON) Q2 2025 MANAGEMENT VIEW * CEO Sean E. Brynjelsen stated that "it was another record quarter for the company" and described 2025 as "the most exciting time in our history." He highligh... Full story

Yahoo Finance • 9 months ago

Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today ann... Full story

Yahoo Finance • 10 months ago

Adrenal Crisis Market Analysis and Forecast Report 2025-2035 with Competitive Benchmarking of Eton Pharmaceuticals, Antares Pharma, and Pfizer

Company Logo The global adrenal crisis market is witnessing significant growth driven by increasing adrenal insufficiency recognition and rising adrenal crisis incidents. The expanding global prevalence of autoimmune diseases and corticos... Full story

Yahoo Finance • 10 months ago

FDA accepts Eton's NDA for ET-600 desmopressin oral solution

DEER PARK, Ill. - Eton Pharmaceuticals, Inc. (NASDAQ:ETON), a specialty pharmaceutical company with a market capitalization of $386 million and an impressive 323% return over the past year, announced Tuesday that the U.S. Food and Drug Adm... Full story

Yahoo Finance • 10 months ago

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)

- NDA assigned a Target Action Date of February 25, 2026 - - Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovat... Full story

Yahoo Finance • 10 months ago

Eton Pharmaceuticals to join Russell indexes

* Eton Pharmaceuticals (NASDAQ:ETON [https://seekingalpha.com/symbol/ETON]) will be added to the broad-market Russell 3000 and small-cap Russell 2000 Indexes, as part of the 2025 Russell Indexes reconstitution. * The addition is effect... Full story